- Sales (-0.6%) and core operating profit (-8.8%) decreased due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017. Excluding these items, as well as the impact of foreign exchange, sales decreased -1.3% and core operating profit -2.6%, respectively.
- Sales of key global products such as XTANDI® for the treatment of prostate cancer and Betanis® / Myrbetriq® / BETMIGA® for the treatment of overactive bladder ("OAB") grew.
- Operating profit (-22.3%) and profit for the period (-20.2%) on a full basis decreased mainly due to the impact of one-time impairment losses and charges associated with the review of development project plans and the wind-down of research operations of subsidiary Agensys, Inc. being recorded during the first six months of FY2017.
Astellas today announced the financial results for the first nine months of fiscal year 2017 ending March 31, 2018 ("FY2017").
"Key global products including XTANDI® continued to demonstrate steady growth in the first nine months of FY2017. We achieved many milestones including the acquisition of Mitobridge, Inc. in January 2018 by exercising the option right to acquire Mitobridge. The transaction accelerates Astellas’ research and development in diseases associated with mitochondrial dysfunctions," said Yoshihiko Hatanaka, president and CEO, Astellas. "We remain committed to creating innovative medical solutions and delivering value for patients and all stakeholders, as we continue to advance our strategic plan by maximizing the value of our products, creating innovation and pursuing operational excellence."
|
Consolidated Financial Results (April 1, 2017 – December 31, 2017) (core basis) |
||||||
|
(Millions of yen) |
||||||
| First nine months of FY2016 | First nine months of FY2017 | Change (%) |
||||
| Sales | 1,005,587 | 999,443 |
-6,144 |
|||
| Core operating profit | 241,837 | 220,459 |
-21,378 |
|||
| Core profit for the period | 177,189 | 167,877 |
-9,312 |
|||
Quarterly Revenue Highlights
Sales in the first nine months of FY2017 decreased 0.6% compared to those in the corresponding period of the previous fiscal year ("year-on-year") to ¥999.4 billion due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017.
- Oncology franchise
Sales of XTANDI® increased 16.2% year-on-year to ¥219.9 billion. Sales grew steadily in all regions including Japan, the Americas, EMEA1 and the Asia and Oceania region.
- Urology OAB franchise
Sales of Betanis® / Myrbetriq® / BETMIGA® increased 30.0% year-on-year to ¥93.1 billion. Sales increased in all regions of the world. Sales of Vesicare®, however, decreased 12.1% year-on-year to ¥78.5 billion.
- Transplantation franchise
Sales of Prograf® increased 5.6% year-on-year to ¥150.2 billion, and continued to grow in Japan, EMEA and the Asia and Oceania regions.
- Other new and key products
In the Japanese market, continued growth was ach...
(All Rights Reserved)